This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related article  • Related letters  • Similar articles in JAMA  Topic Collections  • Bacterial Infections  • Neurology  • Critical Care/ Intensive Care Medicine  • Adult Critical Care  • Anesthesia  • Substance Abuse/ Alcoholism  • Quality of Care  • Patient Safety/ Medical Error  • Drug Therapy  • Adverse Effects  • Drug Therapy, Other  • Infectious Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

To the Editor: In their randomized trial comparing dexmedetomidine vs midazolam for sedation in critically ill patients, Dr Riker and colleagues¹ found dexmedetomidine to be a safe and effective alternative to midazolam. In the study methods, an optional loading dose of dexmedetomidine (up to 1 µg/kg) was allowed at the investigator's discretion, as recommended in the medication prescribing information.² However, only 20 of 244 dexmedetomidine-treated patients (8.2%) were administered loading doses. Given the relatively low use of a loading dose, it is plausible that the results of the study may have changed if more patients had been administered loading doses. Because of the half life of dexmedetomidine (2 hours),² without a loading dose it may take up to 10 hours for a patient to reach steady state. Clinically, this correlates with patients in the dexmedetomidine group being administered more open-label midazolam on the first day (43% vs 30%, P = .02).

. . . [Full Text of this Article]

Christopher Paciullo, PharmD
capaci2@uky.edu
University of Kentucky HealthCare
Lexington

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients: A Randomized Trial
Richard R. Riker, Yahya Shehabi, Paula M. Bokesch, Daniel Ceraso, Wayne Wisemandle, Firas Koura, Patrick Whitten, Benjamin D. Margolis, Daniel W. Byrne, E. Wesley Ely, Marcelo G. Rocha, and for the SEDCOM (Safety and Efficacy of Dexmedetomidine Compared With Midazolam) Study Group
JAMA. 2009;301(5):489-499.
ABSTRACT | FULL TEXT  

RELATED LETTERS

Comparing Dexmedetomidine With Midazolam for Sedation of Patients in the ICU
Jack DePriest and Luis Gonzalez, III
JAMA. 2009;301(23):2439.
EXTRACT | FULL TEXT  

Comparing Dexmedetomidine With Midazolam for Sedation of Patients in the ICU
Mohamed Y. Rady, Bhavesh M. Patel, and Joel S. Larson
JAMA. 2009;301(23):2439-2440.
EXTRACT | FULL TEXT  

Comparing Dexmedetomidine With Midazolam for Sedation of Patients in the ICU
Amit Gupta, David Lee, and Mark Su
JAMA. 2009;301(23):2440-2441.
EXTRACT | FULL TEXT  

Comparing Dexmedetomidine With Midazolam for Sedation of Patients in the ICU—Reply
Richard R. Riker, Yahya Shehabi, and Marcelo G. Rocha
JAMA. 2009;301(23):2441-2442.
EXTRACT | FULL TEXT